Greenwich LifeSciences Stock (NASDAQ:GLSI)


RevenueOwnershipFinancialsChart

Previous Close

$13.44

52W Range

$8.00 - $21.44

50D Avg

$14.04

200D Avg

$14.16

Market Cap

$172.06M

Avg Vol (3M)

$29.01K

Beta

3.29

Div Yield

-

GLSI Company Profile


Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

3

IPO Date

Sep 25, 2020

Website

GLSI Performance


GLSI Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-9.33M$-8.04M$-4.60M
Net Income$-8.89M$-7.61M$-4.54M
EBITDA$-9.33M$-8.04M$-4.59M
Basic EPS$-0.69$-0.59$-0.35
Diluted EPS$-0.69$-0.59$-0.35

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
XFORX4 Pharmaceuticals, Inc.
AVXLAnavex Life Sciences Corp.
NXTCNextCure, Inc.
RVPHReviva Pharmaceuticals Holdings, Inc.
DAWNDay One Biopharmaceuticals, Inc.
VRPXVirpax Pharmaceuticals, Inc.
PDSBPDS Biotechnology Corporation
ACXPAcurx Pharmaceuticals, Inc.
TERNTerns Pharmaceuticals, Inc.
INZYInozyme Pharma, Inc.
EYENEyenovia, Inc.
IMMPImmutep Limited
MNOVMediciNova, Inc.
ABOSAcumen Pharmaceuticals, Inc.
ENTXEntera Bio Ltd.
AMLXAmylyx Pharmaceuticals, Inc.